Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
featured
Published in COVID-19 and
1 other channel

Journal Scan / Research · July 21, 2022

Thromboembolic and Thrombocytopenic Events After the Administration of AZD1222, BNT162b2, and mRNA-1273 COVID-19 Vaccines

JAMA Network Open

 

 Save  Recommend
 Share

Additional Info

JAMA Network Open
Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
JAMA Netw Open 2022 Jun 01;5(6)e2217375, J Dag Berild, V Bergstad Larsen, E Myrup Thiesson, T Lehtonen, M Grøsland, J Helgeland, J Wolhlfahrt, J Vinsløv Hansen, AA Palmu, A Hviid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated